Key terms
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest HALO news
Yesterday
10:55am ET
Buy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential
Apr 16
7:41am ET
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
Apr 08
6:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Marinus (MRNS) and Halozyme (HALO)
Apr 08
4:00am ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)
Mar 08
7:26am ET
TD Cowen Reaffirms Their Buy Rating on Halozyme (HALO)
Feb 29
5:47am ET
Buy Rating Affirmed for Halozyme on Strong ENHANZE Technology Prospects and Robust Partnership Pipeline
Feb 29
5:41am ET
Halozyme initiated with an Outperform at TD Cowen
Feb 26
7:30am ET
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)
Feb 26
12:10am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Immuneering (IMRX), Halozyme (HALO) and Repligen (RGEN)
Feb 21
8:11am ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), NeoGenomics (NEO) and Ardelyx (ARDX)
Feb 21
6:09am ET
Halozyme price target raised to $50 from $48 at H.C. Wainwright
Feb 21
1:11am ET
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), GeneDx Holdings (WGS) and Halozyme (HALO)
Feb 20
9:30pm ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO) and AbCellera Biologics (ABCL)
Feb 20
4:10pm ET
Halozyme sees FY24 royalty revenue $500M-$525M
Feb 20
4:03pm ET
Halozyme announces new $750M share repurchase plan
Feb 20
4:03pm ET
Halozyme backs FY24 adjusted EPS view $3.55-$3.90, consensus $3.51
Feb 20
4:02pm ET
Halozyme reports Q4 adjusted EPS 82c, consensus 82c
Feb 14
12:15pm ET
Buy Rating Affirmed for Halozyme: Projected Royalty Revenue and EBITDA Surge to $1 Billion by 2027
Feb 13
7:20am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: AptarGroup (ATR), Halozyme (HALO) and Bausch Health Companies (BHC)
Jan 29
4:30pm ET
Halozyme announces Takeda received EC approval for HYQVIA
Jan 22
3:10pm ET
Analysts Conflicted on These Healthcare Names: Generation Bio (GBIO), RegenXBio (RGNX) and Halozyme (HALO)
Jan 22
1:40pm ET
Analysts Offer Insights on Healthcare Companies: ATAI Life Sciences (ATAI), Halozyme (HALO) and Natera (NTRA)
Jan 22
1:31pm ET
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Vor Biopharma (VOR) and Clearside Biomedical (CLSD)
Jan 22
12:35pm ET
Buy Rating for HALO: Long-Term Royalty Growth and Robust Financial Outlook
Jan 18
8:33am ET
Halozyme announces approval for Vydura in Japan
Jan 18
6:14am ET
Halozyme price target lowered to $48 from $61 at H.C. Wainwright
No recent press releases are available for HALO
HALO Financials
Key terms
Ad Feedback
HALO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
HALO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range